GlassScriptPhysician profile
Kashif Ahmed
NPI 1023227030
$8,084.70
in general payments reported to CMS, 2019-2025
34 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $1,075 · 2021: $1,283 · 2022: $1,109 · 2023: $1,273 · 2024: $1,169 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,264 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.31 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,192.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,077.79 | 2019-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $781.61 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $758.78 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Novo Nordisk INC | $708.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.61 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $373.59 | 2019-2025 | |
| Abbott Laboratories | $285.53 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $281.47 | 2019-2021 | |
| Shield Therapeutics INC | $205.16 | 2023-2024 | Accrufer |
| Merck Sharp & Dohme LLC | $190.38 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Amgen INC. | $188.96 | 2023-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.01 | 2020-2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $172.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $167.48 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $124.53 | 2022-2023 | |
| Allergan, INC. | $108.07 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.42 | 2025 | Caplyta |
| Exact Sciences Corporation | $91.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $87.10 | 2020-2024 | Nexletol |
| Corcept Therapeutics | $59.02 | 2025 | Korlym |
| Kyowa Kirin, INC. | $58.57 | 2023-2025 | Nourianz |
| Insulet Corporation | $46.01 | 2023 | Omnipod |
| Amarin Pharma, INC. | $37.55 | 2019-2020 | |
| Medline Industries LP | $33.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $25.09 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $23.56 | 2023 | Hetlioz |
| Astellas Pharma US INC | $21.94 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $20.02 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.38 | 2023 | Linzess |
| Idorsia Pharmaceuticals US INC | $19.32 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $19.10 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.17 | 2022 | |
| Dexcom, INC. | $13.47 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.